Oppenheimer Maintains Outperform on Soleno Therapeutics, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) and increased the price target from $44 to $47.
January 02, 2024 | 4:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reaffirmed Soleno Therapeutics' Outperform rating and raised the price target from $44 to $47, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Leland Gershell suggests a strong conviction in the future performance of Soleno Therapeutics. This is likely to be viewed positively by investors and could lead to a short-term increase in the stock price as market sentiment around the company improves.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100